Pazopanib and ARQ 197 for Advanced Solid Tumors

NCT01468922 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Pazopanib
DRUG: ARQ 197

Sponsor

National Cancer Institute (NCI)